Our CEO Dr. Hanadie Yousef presented updates on Juvena’s platform and advancing pipeline of tissue restorative biologics for muscle and metabolic diseases at Biocom California’s Global Life Science Partnering and Investor Conference
Hanadie Yousef, Juvena’s CEO and co-founder, participated in #BiotechCEOSisterhood, #Breaking7%, and PINK Tuesday events, connecting with leaders and allies to drive innovation and collaboration
Dr. Hanadie Yousef, CEO and co-founder of Juvena, and Dr. Austin Wang, Corporate Development Manager, hosted an executive roundtable on weight loss for longevity at the #WuXiGlobalForum, fostering engaging discussions with industry leaders
Juvena’s CEO and co-founder, Dr. Hanadie Yousef, shared insights on “Enhancing Longevity: Delaying the Diseases That Age Us” at the #BiotechShowcase panel and highlighted Juvena’s progress, including the upcoming clinical trials for JUV-161
As a Tech Pioneer company, CEO Hanadie Yousef participated in the third Annual Meeting of the Innovator Communities at the World Economic Forum’s New York office, amongst over 80 Founders and CEOs
CEO Dr. Hanadie Yousef discusses Juvena’s AI-enabled platform for mapping the therapeutic potential of stem cell secreted proteins and engineering restorative biologics for age-related and chronic diseases on the podcast Impact AI
Dr. Jeremy O’Connell, our CSO, participated as a panelist at the Gerontological Society of America (GSA) Annual Meeting, discussing the role of NIA programs in advancing JUV-161 from discovery to development and fostering innovation in aging research
Thach Mai, Director of Discovery and Platform, and Priya Handa, Director of Translational Biology, were speakers at the 16th Drug Discovery Strategic Summit in San Francisco. Thach presented on our AI-enabled platform for therapeutic discovery, while Priya spoke about JUV-112, a novel approach to weight loss and metabolic health
Juvena shares updates with the DM community about our muscle regenerating fusion protein, JUV-161 in the “Meet the Myotonic Dystrophy Drug Developers” webinar
